DOC-MEK
Recruitment closed MAY 2012
Trial Status: Complete
This is a multi-centre randomised trial of docetaxel with or without AZD6244 in advanced melanoma
BRIEF SUMMARY
A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma. To determine the efficacy and tolerability of the combination of the selective MEK inhibitor AZD6244 with docetazel in patients with wild-type BRAF metastatic melanoma.
Objectives
Primary:
- To assess the efficacy of AZD6244 in combination with docetaxel, compared with docetaxel alone, in first line patients with wild type BRAF advanced malignant melanoma.
Secondary:
- To further assess the efficacy of AZD6244 in combination with docetaxel, compared with docetaxel alone, in first line patients with wild type BRAF advanced malignant melanoma.
- To assess the safety and tolerability of AZD6244 in combination with docetaxel compared with docetaxel alone.